CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.
Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
合成生物学是一门新兴的交叉研究领域,遵循工程学原理对生物系统进行重新设计和构建,以实现特定用途。嵌合抗原受体(CAR)T细胞是合成生物学最具代表性的临床应用之一,近年来已在晚期血液系统恶性肿瘤治疗中取得显著成效。然而,多项尚未解决的障碍限制了CAR-T 细胞疗法的广泛应用,包括治疗相关毒性、抗原异质性、抗原逃逸、CAR-T 细胞持续存在和扩增能力不足,尤其是其归巢、浸润实体瘤并在其中存活的效率低下。因此,亟须创新CAR设计,以提高疗效并减少副作用;研究者也正在开发多种方法克服这些局限。本文总结现有生物工程策略,并从合成生物学角度讨论未来发展方向。
Synthetic biology is a novel interdisciplinary research area following engineering principles to redesign and construct biological systems for useful purposes. As one of the most notable clinically relevant application of synthetic biology, chimeric antigen receptor (CAR) T cells have demonstrated tremendous success for the treatment of advanced hematological malignancies in recent years.
However, various unsolved obstacles limit the widespread application of CAR T cell therapies, including treatment-associated toxicities, antigen heterogeneity, antigen escape, poor CAR T cell persistence and expansion, and particularly inefficient homing, infiltrating into, and surviving within solid tumors. Accordingly, to improve therapeutic efficacy and minimize side effects, innovative CAR design becomes urgently necessary, and researchers are developing numerous methods to overcome the limitations.
Here we summarize currently available bioengineering strategies and discuss the future development from a viewpoint of synthetic biology.
MEMBER ACCOUNT
登录成功会直接打开下一页。